STOCK TITAN

Xenetic Biosciences, Inc. - XBIO STOCK NEWS

Welcome to our dedicated page for Xenetic Biosciences news (Ticker: XBIO), a resource for investors and traders seeking the latest updates and insights on Xenetic Biosciences stock.

Xenetic Biosciences, Inc. (NASDAQ: XBIO) is a clinical-stage biopharmaceutical company specializing in the discovery, research, and development of next-generation biologic drugs and novel oncology therapeutics. The company's proprietary drug development platforms include PolyXen™, which enhances the half-life and other pharmacological properties of biologic drugs.

Xenetic’s lead investigational product candidates comprise the FDA orphan-designated oncology therapeutic Sodium Cridanimod for progesterone receptor-negative endometrial cancer, and a polysialylated form of erythropoietin for treating anemia in pre-dialysis patients with chronic kidney disease. Xenetic is also collaborating with Shire PLC (formerly Baxalta, Baxter Incorporated, and Baxter Healthcare) to develop polysialylated blood coagulation factors, including a next-generation Factor VIII.

In the immune-oncology space, Xenetic is advancing XCART, a personalized CAR T platform technology, and the DNase platform aimed at improving existing treatments by targeting neutrophil extracellular traps (NETs) implicated in cancer progression and resistance. The company is working towards Phase 1 clinical development for pancreatic carcinoma and other solid tumors.

Recent financial updates reveal that Xenetic ended Q2 2023 with approximately $10.7 million in cash and no debt. The company reported a net loss of $1.1 million for Q3 2023 and continued to secure strategic collaborations and advance its DNase-based oncology program.

Rhea-AI Summary

Xenetic Biosciences (NASDAQ: XBIO), a biopharmaceutical company focused on immune-oncology technologies, will present at the H.C. Wainwright Global Investment Conference on May 25, 2022, at 4:00 PM ET. CEO Jeffrey F. Eisenberg will deliver the presentation in Miami, FL, and virtually. The management team will also be available for one-on-one meetings with investors. A live video webcast will be accessible on the Company's website and archived for 90 days. Xenetic is advancing therapies targeting Neutrophil Extracellular Traps and developing CAR T platform technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
conferences
-
Rhea-AI Summary

Xenetic Biosciences (NASDAQ: XBIO) reported its first quarter 2022 financial results, highlighting a net loss of approximately $1.6 million and cash reserves of $16.2 million. The company has completed an exclusive licensing agreement with CLS Therapeutics for a DNase-based oncology platform aimed at enhancing cancer treatment outcomes. The focus is on advancing this platform for Phase 1 clinical development targeting locally advanced or metastatic solid tumors, with an IND filing anticipated by the end of 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.45%
Tags
-
Rhea-AI Summary

Xenetic Biosciences (NASDAQ: XBIO) has announced a transaction with CLS Therapeutics to develop a DNase-based oncology platform, which aims to enhance the efficacy of existing therapies for solid tumors. This includes an exclusive license for DNases in cancer treatment, entailing an upfront payment of $500,000, issuance of shares, and future milestone payments potentially reaching $13 million. The company plans to conduct a Phase 1 clinical study targeting locally advanced or metastatic cancers. The platform seeks to address issues related to Neutrophil Extracellular Traps (NETs), which may hinder cancer treatment outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.83%
Tags
none
Rhea-AI Summary

Xenetic Biosciences (NASDAQ: XBIO) reported a net loss of $5.6 million for the year ended December 31, 2021, with research and development expenses rising to $3.2 million. The company ended the year with cash reserves of approximately $18.2 million and working capital of about $17.3 million, up from $11.4 million in 2020. Their XCART platform is advancing toward IND-enabling studies, while royalty payments from the PolyXen technology reached $1.2 million, a 166% increase from the previous year. The XCART program targets a potential global market of over $7 billion annually.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.76%
Tags
-
Rhea-AI Summary

Xenetic Biosciences (NASDAQ: XBIO) is advancing its XCART platform towards IND-enabling studies, backed by a strengthened cash position from a recent $12.5 million private placement. The company reported a net loss of $1.4 million for Q3 2021, with R&D expenses rising by 36.1% to $0.8 million. Additionally, royalty streams have grown through its license agreement with PolyXen®, bringing in approximately $0.3 million in royalties. With working capital at $19.5 million, Xenetic is positioned to pursue its innovative cancer therapies effectively.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
-
Rhea-AI Summary

Xenetic Biosciences (NASDAQ: XBIO) announced a Notice of Allowance from the USPTO for its patent application covering its XCART personalized CAR T therapy. This platform targets tumor-specific neoantigens and aims to improve cancer treatment effectiveness. CEO Jeffrey Eisenberg highlighted this as a significant milestone for the XCART program, which is currently in pre-clinical development for Non-Hodgkin lymphoma. The resulting U.S. patent is expected to expire in 2038, enhancing the company's intellectual property portfolio.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Xenetic Biosciences (NASDAQ: XBIO) has announced that CEO Jeffrey F. Eisenberg will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will focus on the Company's personalized CAR T platform technology, XCART™, designed to target patient-specific tumor neoantigens. A video webcast of the presentation will be available on-demand starting September 13 at 7:00 AM ET, with a replay accessible for 90 days. The Company is also leveraging its PolyXen® platform for drug delivery improvements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
conferences
-
Rhea-AI Summary

Xenetic Biosciences (NASDAQ: XBIO) reported a net loss of approximately $1.1 million for Q2 2021, with R&D expenses increasing 70.4% to $0.5 million due to advancements in its XCART platform. The company strengthened its position through a $12.5 million private placement and saw royalty growth from its PolyXen technology, totaling about $0.3 million in royalties generated from Takeda's sublicensee. The company is progressing towards IND-enabling studies in the U.S., aiming to address a significant market opportunity in oncology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.48%
Tags
-
Rhea-AI Summary

Xenetic Biosciences (NASDAQ: XBIO) announced the closure of a private placement, raising approximately $12.5 million by issuing 4,629,630 shares at $2.70 each. The offering included warrants that could generate an additional $15.3 million if fully exercised. Proceeds will be used for general working capital. The shares were sold under a private placement exemption and the company plans to register them within 30 days. Xenetic focuses on advancing its XCART technology for cancer treatment and leveraging its PolyXen drug delivery platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.26%
Tags
none
Rhea-AI Summary

Xenetic Biosciences (NASDAQ: XBIO) has announced a definitive agreement for a private placement with a healthcare-focused institutional investor. The transaction involves the sale of 4,629,630 shares of common stock at $2.70 per share, amounting to $12.5 million in gross proceeds. The investor will also receive warrants to purchase an equal number of shares at $3.30 per share. The placement is expected to close around July 28, 2021. The funds will be utilized for general working capital purposes, aiding the advancement of their XCART technology for cancer treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.24%
Tags
none

FAQ

What is the current stock price of Xenetic Biosciences (XBIO)?

The current stock price of Xenetic Biosciences (XBIO) is $3.86 as of January 10, 2025.

What is the market cap of Xenetic Biosciences (XBIO)?

The market cap of Xenetic Biosciences (XBIO) is approximately 6.0M.

What is Xenetic Biosciences' main focus?

Xenetic Biosciences focuses on the discovery, research, and development of next-generation biologic drugs and novel oncology therapeutics.

What are the primary platforms used by Xenetic Biosciences?

Xenetic's primary platforms include PolyXen™, XCART, and the DNase platform.

What are Xenetic Biosciences' lead investigational products?

Xenetic's lead products include Sodium Cridanimod for treating progesterone receptor-negative endometrial cancer and a polysialylated form of erythropoietin for anemia in pre-dialysis chronic kidney disease patients.

Who are Xenetic Biosciences' key partners?

Xenetic collaborates with Shire PLC to develop polysialylated blood coagulation factors.

What is the focus of Xenetic's DNase platform?

Xenetic's DNase platform aims to improve outcomes of existing cancer treatments by targeting neutrophil extracellular traps (NETs).

What are the company's recent financial highlights?

Xenetic reported a net loss of $1.1 million for Q3 2023 and ended Q2 2023 with approximately $10.7 million in cash and no debt.

What is the goal of Xenetic's XCART technology?

XCART is a personalized CAR T platform technology intended to advance immune-oncology treatments.

What are the company’s plans for its DNase-based oncology program?

Xenetic aims to advance its DNase-based oncology program towards Phase 1 clinical development for treating pancreatic carcinoma and other solid tumors.

How does the PolyXen™ platform benefit biologic drugs?

PolyXen™ enhances the half-life and other pharmacological properties of next-generation biologic drugs.

Where can I find more information about Xenetic Biosciences?

For more information, visit the company’s website at www.xeneticbio.com and connect on social media platforms like Twitter, LinkedIn, and Facebook.
Xenetic Biosciences, Inc.

Nasdaq:XBIO

XBIO Rankings

XBIO Stock Data

5.95M
1.25M
19.06%
2.1%
0.96%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
FRAMINGHAM